
	Three Months Ended June 30, 2025
	Nucleic Acid Production		Biologics Safety Testing		Total
Revenue	$	31,085	$	16,312	$	47,397

Less:
Cost of revenue (1)	24,407		3,002
Selling and marketing (1)	6,367		745
General and administrative (1)	5,179		1,186
Research and development (1)	2,496		516
Other segment items (2)	(94)		3
Adjusted EBITDA	(7,270)		10,860		$	3,590
Reconciliation of total reportable segments’ Adjusted EBITDA to loss before income taxes
Amortization					(7,200)
Depreciation					(5,957)
Interest expense					(6,815)
Interest income					3,030
Corporate costs, net of eliminations					(14,000)
Other adjustments:
Acquisition contingent consideration					(140)
Acquisition integration costs					(831)
Stock-based compensation					(6,789)
Merger and acquisition related expenses					(92)


Acquisition related tax adjustment					(4,153)

Executive leadership transition costs (3)					(2,007)
Goodwill impairment					(30,449)
Property and equipment impairment					(1,052)


Other					(1,260)
Loss before income taxes					(74,125)
Income tax benefit					4,288
Net loss					$	(69,837)


	Six Months Ended June 30, 2025
	Nucleic Acid Production		Biologics Safety Testing		Total
Revenue	$	59,835	$	34,412	$	94,247

Less:
Cost of revenue (1)	49,229		5,803
Selling and marketing (1)	12,135		1,575
General and administrative (1)	9,694		2,399
Research and development (1)	4,994		1,101
Other segment items (2)	(47)		3
Adjusted EBITDA	(16,170)		23,531		$	7,361
Reconciliation of total reportable segments’ Adjusted EBITDA to loss before income taxes
Amortization					(14,230)
Depreciation					(11,650)
Interest expense					(13,593)
Interest income					6,255
Corporate costs, net of eliminations					(28,320)
Other adjustments:
Acquisition contingent consideration					(140)
Acquisition integration costs					(1,598)
Stock-based compensation					(17,192)
Merger and acquisition related expenses					(1,270)


Acquisition related tax adjustment					(4,082)

Executive leadership transition costs (3)					(2,007)
Goodwill impairment					(42,884)
Property and equipment impairment					(1,052)


Other					(2,414)
Loss before income taxes					(126,816)
Income tax benefit					4,126
Net loss					$	(122,690)


	Three Months Ended June 30, 2024
	Nucleic Acid Production		Biologics Safety Testing		Total
Revenue	$	54,586	$	14,837	$	69,423

Less:
Cost of revenue (1)	23,854		3,102
Selling and marketing (1)	5,728		702
General and administrative (1)	4,886		1,158
Research and development (1)	2,658		509
Other segment items (2)	7		1
Adjusted EBITDA	17,453		9,365		$	26,818
Reconciliation of total reportable segments’ Adjusted EBITDA to loss before income taxes
Amortization					(6,869)
Depreciation					(5,556)
Interest expense					(11,939)
Interest income					7,086
Corporate costs, net of eliminations					(13,829)
Other adjustments:
Acquisition contingent consideration					1,195
Acquisition integration costs					(1,224)
Stock-based compensation					(13,763)



Acquisition related tax adjustment					(2,554)



Restructuring costs (4)					8

Other					(228)
Loss before income taxes					(20,855)
Income tax benefit					2,435
Net loss					$	(18,420)


	Six Months Ended June 30, 2024
	Nucleic Acid Production		Biologics Safety Testing		Total
Revenue	$	100,602	$	33,000	$	133,602

Less:
Cost of revenue (1)	48,478		4,856
Selling and marketing (1)	10,121		1,379
General and administrative (1)	9,327		2,435
Research and development (1)	5,121		1,038
Other segment items (2)	14		1
Adjusted EBITDA	27,541		23,291		$	50,832
Reconciliation of total reportable segments’ Adjusted EBITDA to loss before income taxes
Amortization					(13,738)
Depreciation					(10,342)
Interest expense					(22,803)
Interest income					14,296
Corporate costs, net of eliminations					(30,048)
Other adjustments:
Acquisition contingent consideration					1,195
Acquisition integration costs					(3,722)
Stock-based compensation					(25,820)
Merger and acquisition related expenses					(30)


Acquisition related tax adjustment					(2,441)



Restructuring costs (4)					(11)

Other					(632)
Loss before income taxes					(43,264)
Income tax benefit					2,164
Net loss					$	(41,100)

(3)For both the three and six months ended June 30, 2025, stock-based compensation benefit of $3.3 million primarily related to forfeited stock awards in connection with the Executive Leadership Transition is included on the stock-based compensation line item.

(4)For the three months ended June 30, 2024, there was an immaterial amount of stock-based compensation expense in connection with the restructuring included in the stock based-compensation line item. For the six months ended June 30, 2024, stock-based compensation benefit of $1.2 million related to forfeited stock awards in connection with the restructuring is included on the stock-based compensation line item.